Rethinking Retroperitoneal Sarcoma Surgery: Is Less Really More?
"A new study challenges the 'one-size-fits-all' approach to retroperitoneal sarcoma surgery, advocating for personalized resection strategies."
Retroperitoneal sarcomas (RPS), cancers lurking behind the abdominal lining, pose a significant surgical challenge. The standard approach involves removing the tumor along with any organs it touches, aiming for a complete resection. However, this aggressive strategy hasn't always translated into improved long-term survival for patients.
This reality has sparked a debate: is a more extensive surgery always better? Some European centers have experimented with wider resections, removing even seemingly uninvolved organs to decrease the chance of the cancer returning locally. While this approach sometimes lowers recurrence rates, it hasn't consistently boosted overall survival and leads to more complications.
To address this controversy, a new study has investigated the rationale behind individual organ resections in RPS surgery. The goal was to determine the extent to which cancer cells had invaded organs removed during surgery, paving the way for a more tailored approach to resection.
A Rare but Aggressive Cancer with Limited Curative Options
Retroperitoneal sarcomas (RPS) are characterized by a low incidence rate but a high degree of aggressiveness, with primary retroperitoneal liposarcoma alone accounting for approximately 10–15% of all soft tissue sarcoma cases and its incidence gradually increasing. Surgical resection remains the cornerstone of curative treatment, as surgery currently stands as the only curative option for these tumors. However, the complexity of RPS—owing to their proximity to vital structures—continues to lead to high local recurrence rates after surgery alone. A National Cancer Data Base study of 6,950 patients with primary RPS who underwent surgical resection between 1998 and 2011 found that hospital case volume significantly impacts patient outcomes, raising concerns about where these complex procedures are performed.
The Conventional Surgical Paradigm and Its Inherent Challenges
The standard surgical approach for retroperitoneal sarcomas has historically centered on aggressive resection with the goal of achieving complete macroscopic removal of the tumor, often en bloc with adjacent organs. While this approach is widely regarded as necessary to maximize the chance of cure, it carries substantial morbidity given the anatomical complexity of the retroperitoneum and the proximity of tumors to major vascular structures and organs. The lack of randomized controlled trials defining the precise boundaries of what constitutes an adequate resection means that surgeons often rely on institutional experience and consensus rather than definitive evidence-based guidelines.
Evolving Understanding of a Complex Disease
The surgical management of retroperitoneal sarcomas has evolved considerably over the past several decades, driven by growing insights into tumor biology and improvements in surgical and perioperative care. Early approaches prioritized maximal surgical excision without a nuanced understanding of histological subtypes, but the recognition that different sarcoma subtypes behave biologically distinct has shifted the field toward histology-driven, individualized treatment strategies. This foundational shift from a one-size-fits-all surgical mentality to a more tailored approach represents one of the most significant milestones in RPS management.
The Key to Personalized Resection: Understanding Organ Invasion
The recent study highlights that the likelihood of cancer cells invading adjacent organs (histopathologic organ invasion, or HOI) can be predicted by the specific type of sarcoma and the reason for the organ's removal. This information is crucial for guiding surgeons in determining the minimum extent of resection needed. The study found that organs removed as part of a more extensive, "en bloc" resection (removing the tumor and surrounding tissues as a single block) often showed no evidence of HOI.
- Anatomical Considerations: Factors like the involvement of blood vessels supplying the organ and whether the tumor encases the organ are crucial.
- Tumor Biology: The specific type of sarcoma plays a significant role, influencing how the cancer spreads locally and to distant sites, and ultimately impacting survival.
Multidisciplinary Care and the Push for Better Outcomes
A 2023 updated review by R. Alvarez and colleagues, cited by 19 publications, underscored that the treatment of retroperitoneal sarcomas poses significant challenges owing to their infrequency, clinical and histologic heterogeneity, and unique anatomical considerations. Building on this, a 2024 Frontiers in Oncology review by Garcia-Ortega and colleagues (cited by 22) argued that the treatment of RPS is significantly enhanced by a multidisciplinary team (MDT) approach, particularly when patients are managed within specialist sarcoma centers. Five-year survival rates for RPS remain highly variable, ranging from 12% to 70%, reflecting the heterogeneity of the disease. Earlier systematic work by Wang and colleagues in 2018 (cited by 44) reinforced that complete surgical resection remains the only chance for potential cure, while acknowledging that management of RPS can be exceptionally challenging due to tumor size and location.
Questioning the Extent of Surgery and the Limits of Evidence
Despite the prevailing emphasis on aggressive surgery, a systematic review published in PLOS ONE (2022) concluded that definitive evidence to guide clinical practice on the principles of surgery for retroperitoneal sarcomas is still lacking. The review specifically sought to assess the relative benefits and disadvantages of an aggressive surgical approach with contiguous organ resection, the association between surgical resection margins and survival—areas where the evidence base remains incomplete. A 2025 systematic review further noted that neoadjuvant therapies, often used to shrink tumors preoperatively, have shown limited response and efficacy in RPS, with any benefit being highly dependent on histological subtype. These gaps in evidence raise important questions about whether more extensive surgery truly translates to better outcomes for all patients.
Balancing Resection Extent Against Morbidity and Recurrence
The extent of surgical resection is widely regarded as a crucial determinant of both local control and survival in retroperitoneal sarcomas, yet aggressive treatment frequently results in high rates of local recurrence and significant morbidity. A 2025 Frontiers in Oncology editorial highlighted that RPS present a formidable challenge in surgical oncology due to their rarity, anatomical complexity, frequent involvement of critical structures, and pronounced histological heterogeneity—all of which persist despite aggressive treatment paradigms. Management has evolved with time, championed partly by better understanding of tumor biology and improvements in perioperative care, but this evolution has not eliminated the fundamental tension between achieving complete resection and preserving patient quality of life.
The Future of RPS Treatment: A Data-Driven Approach
This research lays the groundwork for collecting prospective data to inform surgical decision-making based on specific organ and sarcoma types. The Transatlantic RPS Working Group (TARPSWG.org) is leading the charge, establishing treatment guidelines and building a platform to study management strategies tailored to specific sarcoma subtypes.
Where the Field Stands Today
The current body of evidence paints a complex picture: surgery remains the only curative option for retroperitoneal sarcomas, yet the optimal extent of that surgery continues to be debated. The field has increasingly recognized that treatment must be individualized based on histological subtype, tumor location, and patient factors—moving away from a uniformly aggressive surgical philosophy. While multidisciplinary care at specialist centers is now considered best practice, the reality of access to such care varies widely, and many patients are still treated outside optimal settings.
Uncharted Territory in RPS Management
The path forward for retroperitoneal sarcoma treatment will likely involve continued refinement of neoadjuvant and adjuvant therapies tailored to specific histological subtypes, as well as the integration of molecular and genomic profiling into treatment planning. Prospective clinical trials—long hampered by the rarity of these tumors—remain essential to resolve the persistent questions around surgical margins, the role of organ-sparing approaches, and the true value of neoadjuvant radiation or chemotherapy. International collaborative networks and registries represent a promising avenue for generating the large-scale evidence that single-center studies cannot provide.
The Centrality of Specialized, Multidisciplinary Care
A 2023 analysis in Current Oncology emphasized that surgery for retroperitoneal sarcoma should be performed by a surgical oncologist with sub-specialization in this disease and within the context of a multidisciplinary team of sarcoma specialists. This recommendation reflects a broader systemic challenge: RPS are so rare that many general oncologists and surgeons encounter them infrequently, yet the complexity of the disease demands concentrated expertise. Ensuring equitable access to specialist sarcoma centers remains one of the most pressing structural challenges in the management of this disease.
Real-World Data and Patient Outcomes Beyond the Trial Setting
A real-world multicenter study by the Turkish Oncology Group, published in 2021, aimed to demonstrate factors affecting survival in retroperitoneal sarcomas treated with upfront surgery, reflecting the importance of data from routine clinical practice rather than solely controlled trial settings. Complementing this, multi-centre retrospective cohort studies have shown that treatment of primary RPS at high-volume and/or specialist sarcoma centers is associated with increased rates of surgical resection, complete macroscopic resection (R0/1), greater use of peri-operative radiotherapy and/or chemotherapy, and decreased peri-operative morbidity. These findings carry profound implications for patients: where and by whom a patient is treated can meaningfully influence not only the surgical outcome but their broader trajectory of care and survival.
The goal is to move away from a 'one-size-fits-all' approach to a more nuanced, data-driven strategy guided by tumor biology and anatomical considerations. The results of the European Organization for Research and Treatment of Cancer (EORTC) phase 3 trial (STRASS), investigating the role of preoperative radiation therapy, will be a crucial step in refining local control strategies for RPS.
Further research is needed to standardize margin assessment (determining if cancer cells are present at the edge of the removed tissue) and to clarify what exactly constitutes 'organ invasion'. While wider resections may improve the chances of complete tumor removal, the benefit of converting a close margin (R1 resection) to a clear margin (R0 resection) remains uncertain and warrants further investigation.